CR-PCa patients treated with abiraterone who were ARV7-high and PSA-positive had a median of 5.6 months to treatment failure, which was significantly decreased compared to 8.1 months for ARV7-low and PSA-positive patients and 21.1 months for PSA-negative patients [87]. Here, KLK3 is linked to posterior cortical atrophy.